Floatz logo

Bet Bromodomain Inhibitor Zen-3694

Metastatic Prostate Carcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
65/ 100

Competitive context

251 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

Bet Bromodomain Inhibitor Zen-3694 is also rated in:

Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
62 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →